Moderna, Inc. (MRNA)
Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science Transcript
Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science Transcript
Moderna (MRNA) Rises As Market Takes a Dip: Key Facts
Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.
FDA Votes in Favor of Benefit-Risk Profile for Moderna's Flu Vaccine
Moderna said the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 50 through 64 years old, and in adults 65 years of age and older.
US FDA advisers vote in favor of Moderna's flu vaccine
The U.S. Food and Drug Administration's advisers on Thursday backed approval of Moderna's flu vaccine in adults aged 50 and older, saying its benefits outweigh the risks.
MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
Moderna jumps after FDA briefing documents on mFlusiva appear more constructive than expected ahead of a key advisory panel review.
Moderna (MRNA) Surges 6.3%: Is This an Indication of Further Gains?
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel told the German business daily Handelsblatt on Wednesday.
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again.
US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adults
The U.S. Food and Drug Administration's staff reviewers said preliminary assessment of Moderna's flu shot data may support effectiveness in adults 65 years and older.
Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus
Moderna gains up to $50M from CEPI to advance a Bundibugyo ebolavirus vaccine as the partnership expands amid an ongoing Ebola outbreak.
